Abstract

ABSTRACT

Objective: Coagulase-negative staphylococci (CoNS) are leading causes of healthcare-associated bloodstream infections (BSIs) and pose a significant clinical challenge in intensive care units (ICUs). This study aimed to identify clinical and laboratory parameters associated with 30-day mortality in ICU patients with CoNS-related BSI.

Methods: This retrospective study included patients aged 18 years or older who were hospitalized in the ICU between January 1 and November 1, 2024, and had the same CoNS species isolated from two separate blood culture sets. Demographic characteristics, clinical findings, laboratory results, and microbiological data were evaluated. Factors associated with 30-day mortality were investigated using receiver operating characteristic (ROC) curve analysis and multivariate logistic regression analysis.

Results: A total of 173 patients were included in the study. The median age was 75 years (interquartile range [IQR], 66–81), and 42.8% were female. Staphylococcus epidermidis was the most frequently isolated species (42.2%), and 95.3% of isolates were methicillin-resistant. Septic shock was present in 45% of patients. The 30-day mortality rate was 71.6%. Compared with survivors, nonsurvivors had significantly higher procalcitonin (PCT) levels (1.46 vs 0.58 ng/mL; p=0.002) and lactate levels (2.25 vs 1.97 mmol/L; p=0.044), whereas platelet counts were significantly lower (182 500 vs 282 000/mm³; p<0.001). In multivariate analysis, platelet count ≤194 000/mm³ [odds ratio (OR): 5.94; 95% confidence interval (CI): 2.53–13.97; p<0.001] and PCT level >0.67 ng/mL (OR: 3.14; 95% CI: 1.50–6.57; p=0.002) were independently associated with 30-day mortality.

Conclusion: In patients with CoNS-related BSI, elevated PCT levels and low platelet counts were independently associated with 30-day mortality. These findings may contribute to early prognostic assessment and risk stratification in critically ill patients.

Keywords: Bloodstream infection, coagulase-negative staphylococci, mortality, procalcitonin

Volume 39, Issue 2 Volume 39, Isssue 1 Volume 38, Issue 4 Volume 38, Issue 3 Volume 38, Issue 2 Volume 38, Issue 1 Volume 37, Issue 4 Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1